Vor Biopharma
Focus: Vor Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T stem cell therapy and gene therapy, headquartered in Cambridge, MA. The company is advancing a differentiated pipeline in cell and gene therapy modalities.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
17+3 this month
Stable — net +3 jobs in 30d
10 added, 7 removed. Backfill posture.
Should You Work at Vor Biopharma?
AI assessmentVor Biopharma is a science-driven pre-revenue biotech with promising cell therapy differentiation and multiple Phase 3 catalysts, suitable for early-career scientists and clinical specialists willing to accept funding risk for platform upside.
Why Work Here
- Pioneering CAR-T stem cell therapy platform with two lead programs (VCAR33, VOR33) in acute myeloid leukemia targeting a high-unmet-need oncology indication
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT05309733A Long-term Follow-up Study of Patients Who Received VOR33
N/AHelp build intelligence for Vor Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.